INTRODUCTION: @entity16 leading to morbidity and mortality are not frequent in renal transplant recipients. Here, we report a renal transplant recipient who presented with diminished strength in his limbs probably due to multiple etiologies of @entity39097 , which resolved with intravenous immunoglobulin. CASE PRESENTATION: A 49-year-old Iranian male renal transplant recipient with previous history of @entity8 presented with diminished strength in his limbs one month after surgery. Our @entity1 was on @entity205 , @entity618 and @entity229 . Although a detected @entity5886 was corrected with supplemental @entity1391 , the loss of strength was still slowly progressive and @entity2057 was remarkable in his trunk, upper limb and pelvic girdle. Meanwhile, his cranial nerves were intact. @entity6 was diagnosed and insulin therapy was initiated. In addition, as a high serum @entity205 level was detected, the dose of @entity205 was reduced. Our @entity1 was also put on intravenous @entity4540 due to positive serum cytomegalovirus immunoglobulin M antibody. Despite the reduction of oral @entity205 dose along with medical therapy for the @entity6 , his muscular @entity425 and @entity194 did not improve. One week after administration of intravenous immunoglobulin, a significant improvement was noted in his muscular @entity425 . CONCLUSION: A remarkable response to intravenous immunoglobulin is compatible with an immunological basis for the present condition (post-transplant @entity305 ). In cases of post-transplant @entity305 with a high clinical suspicion of immunological origin, administration of intravenous immunoglobulin may be recommended.

Multiple etiologies of XXXX in a renal transplant recipient: a case report.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['autosomal dominant polycystic kidney disease'] @entity6 :: ('MESH:D003920', 'Disease') :: ['cytomegalovirus infection and diabetes mellitus', 'Post-transplant diabetes mellitus'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity16 :: ('MESH:D009422', 'Disease') :: ['Neurological complications'] @entity305 :: ('MESH:D011115', 'Disease') :: ['polyneuropathy'] @entity425 :: ('MESH:D018908', 'Disease') :: ['weakness'] @entity5886 :: ('MESH:D017674', 'Disease') :: ['hypophosphatemia'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine A', 'cyclosporine'] @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil'] @entity194 :: ('MESH:D001284', 'Disease') :: ['atrophy'] @entity4540 :: ('MESH:D015774', 'Chemical') :: ['ganciclovir'] @entity39097 :: ('MESH:C565773', 'Disease') :: ['axonal sensorimotor polyneuropathy'] @entity2057 :: ('MESH:D009133', 'Disease') :: ['diffuse muscular atrophy']
@entity305 :: (MESH:D011115,Disease) :: ['axonal sensory motor polyneuropathy']
